What Role Is There for Patients In Managed Access Deals?
Executive Summary
Market access deals can make or break routine access to new treatments. So what happens when patient-centricity and deal-making meet? Leela Barham looks at the experience in England.
You may also be interested in...
Industry Calls For Reform of England’s Unused Innovative Medicines Fund
The pharmaceutical industry says financial uncertainties are a key reason why the English Innovative Medicines Fund (IMF) – offering the potential for time-limited funding for promising non-cancer treatments where benefits are uncertain at launch - has still not been used a year after it was put in place. Industry wants the National Health Service to share the financial risk of taking part in the fund.
Ipsen Accuses Government Of Backward Step With Proposed Changes to Statutory Pricing Scheme
Ipsen and other experts have criticized proposals from the UK government on changes to the statutory scheme for the pricing of branded medicines. Plans for differential rebates are seen as too complex, meaning their impact is difficult to predict and they could end up costing the government more.
Almost 3,000 Patients Treated Under UK’s Early Access To Medicines Scheme
Data provided to the Pink Sheet under freedom of information requests show the scale of patient access that has been delivered under the UK’s scheme for early access to products that have yet to receive a marketing authorization.